Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Manuela Schmidinger is active.

Publication


Featured researches published by Manuela Schmidinger.


Journal of Clinical Oncology | 2008

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Manuela Schmidinger; Christoph C. Zielinski; Ursula Vogl; Andja Bojic; Marija Bojic; Christoph Schukro; Marquerite Ruhsam; Michael Hejna; Herwig Schmidinger

PURPOSE Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported in approximately 10% of the patients. Detailed cardiovascular monitoring during TKI treatment may reveal early signs of myocardial damage. PATIENTS AND METHODS In this observational, single-center study, all patients intended for TKI treatment were analyzed for coronary artery disease (CAD) risk factors, history or evidence of CAD, hypertension, rhythm disturbances, and heart failure. Monitoring included assessment of symptoms, ECGs, and biochemical markers (ie, creatine kinase-MB, troponin T). Echocardiography was performed at baseline in selected patients and in all patients who experienced a cardiac event. A cardiac event was defined as the occurrence of increased enzymes if normal at baseline, symptomatic arrhythmia that required treatment, new left ventricular dysfunction, or acute coronary syndrome. RESULTS A total of 86 patients were treated with either sunitinib or sorafenib. Among 74 eligible patients, 33.8% experienced a cardiac event, 40.5% had ECG changes, and 18% were symptomatic. Seven patients (9.4%) were seriously compromised and required intermediate care and/or intensive care admission. All patients recovered after cardiovascular management (ie, medication, coronary angiography, pacemaker implantation, heart surgery) and were considered eligible for TKI continuation. Statistically, there was no significant survival difference between patients who experienced a cardiac event and those who did not experience a cardiac event. CONCLUSION Our observations indicate that cardiac damage from TKI treatment is a largely underestimated phenomenon but is manageable if patients have careful cardiovascular monitoring and cardiac treatment at the first signs of myocardial damage.


The New England Journal of Medicine | 2015

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri; Bernard Escudier; Thomas Powles; Paul N. Mainwaring; Brian I. Rini; Frede Donskov; Hans J. Hammers; Thomas E. Hutson; Jae Lyun Lee; Katriina Peltola; Bruce J. Roth; Georg A. Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y.C. Heng; Manuela Schmidinger; Philip W. Kantoff; Anne E. Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela Schwab; Nizar M. Tannir; Robert J. Motzer

BACKGROUND Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. METHODS We randomly assigned 658 patients to receive cabozantinib at a dose of 60 mg daily or everolimus at a dose of 10 mg daily. The primary end point was progression-free survival. Secondary efficacy end points were overall survival and objective response rate. RESULTS Median progression-free survival was 7.4 months with cabozantinib and 3.8 months with everolimus. The rate of progression or death was 42% lower with cabozantinib than with everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P<0.001). The objective response rate was 21% with cabozantinib and 5% with everolimus (P<0.001). A planned interim analysis showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P=0.005) but did not cross the significance boundary for the interim analysis. Adverse events were managed with dose reductions; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus. Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus. CONCLUSIONS Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).


Lancet Oncology | 2016

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri; Bernard Escudier; Thomas Powles; Nizar M. Tannir; Paul N. Mainwaring; Brian I. Rini; Hans J. Hammers; Frede Donskov; Bruce J. Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y.C. Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N. Sternberg; David F. McDermott; Dana T. Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E. Hutson; Sumanta K. Pal; Robert J. Motzer

BACKGROUND Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here, we report the final overall survival results from this study based on an unplanned second interim analysis. METHODS In this open-label, randomised phase 3 trial, we randomly assigned (1:1) patients aged 18 years and older with advanced or metastatic clear-cell renal cell carcinoma, measurable disease, and previous treatment with one or more VEGFR tyrosine-kinase inhibitors to receive 60 mg cabozantinib once a day or 10 mg everolimus once a day. Randomisation was done with an interactive voice and web response system. Stratification factors were Memorial Sloan Kettering Cancer Center risk group and the number of previous treatments with VEGFR tyrosine-kinase inhibitors. The primary endpoint was progression-free survival as assessed by an independent radiology review committee in the first 375 randomly assigned patients and has been previously reported. Secondary endpoints were overall survival and objective response in all randomly assigned patients assessed by intention-to-treat. Safety was assessed per protocol in all patients who received at least one dose of study drug. The study is closed for enrolment but treatment and follow-up of patients is ongoing for long-term safety evaluation. This trial is registered with ClinicalTrials.gov, number NCT01865747. FINDINGS Between Aug 8, 2013, and Nov 24, 2014, 658 patients were randomly assigned to receive cabozantinib (n=330) or everolimus (n=328). The median duration of follow-up for overall survival and safety was 18·7 months (IQR 16·1-21·1) in the cabozantinib group and 18·8 months (16·0-21·2) in the everolimus group. Median overall survival was 21·4 months (95% CI 18·7-not estimable) with cabozantinib and 16·5 months (14·7-18·8) with everolimus (hazard ratio [HR] 0·66 [95% CI 0·53-0·83]; p=0·00026). Cabozantinib treatment also resulted in improved progression-free survival (HR 0·51 [95% CI 0·41-0·62]; p<0·0001) and objective response (17% [13-22] with cabozantinib vs 3% [2-6] with everolimus; p<0·0001) per independent radiology review among all randomised patients. The most common grade 3 or 4 adverse events were hypertension (49 [15%] in the cabozantinib group vs 12 [4%] in the everolimus group), diarrhoea (43 [13%] vs 7 [2%]), fatigue (36 [11%] vs 24 [7%]), palmar-plantar erythrodysaesthesia syndrome (27 [8%] vs 3 [1%]), anaemia (19 [6%] vs 53 [17%]), hyperglycaemia (3 [1%] vs 16 [5%]), and hypomagnesaemia (16 [5%] vs none). Serious adverse events grade 3 or worse occurred in 130 (39%) patients in the cabozantinib group and in 129 (40%) in the everolimus group. One treatment-related death occurred in the cabozantinib group (death; not otherwise specified) and two occurred in the everolimus group (one aspergillus infection and one pneumonia aspiration). INTERPRETATION Treatment with cabozantinib increased overall survival, delayed disease progression, and improved the objective response compared with everolimus. Based on these results, cabozantinib should be considered as a new standard-of-care treatment option for previously treated patients with advanced renal cell carcinoma. Patients should be monitored for adverse events that might require dose modifications. FUNDING Exelixis Inc.


Nature Reviews Disease Primers | 2017

Renal Cell Carcinoma

James J. Hsieh; Mark P. Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y.C. Heng; James Larkin; Vincenzo Ficarra

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic VHL mutations have been described for some time, more-recent cancer genomic studies have identified mutations in epigenetic regulatory genes and demonstrated marked intra-tumour heterogeneity, which could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed with surgery, whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such as cabozantinib and lenvatinib; immunotherapies, such as nivolumab, have also been added to the armamentarium for metastatic RCC. Here, we provide an overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy.


British Journal of Cancer | 2006

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

U M Vogl; H Zehetgruber; M Dominkus; M Hejna; Christoph Zielinski; Andrea Haitel; Manuela Schmidinger

Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated patients or patients on several different treatment approaches. The aim of this analysis was to define prognostic and predictive factors in patients treated uniformly with a low-dose outpatient cytokine combination. The relationship between patient-, tumour-, and treatment-related factors was analysed in 99 patients with MRCC. These features were first examined in univariate analyses, then a stepwise modelling approach based on Cox regression was used to form a multivariate model. Nuclear grade, metastasectomy – even incomplete – C-reactive protein and lactate dehydrogenase were identified as independent prognostic factors for survival. Patients assigned to three different risk groups had statistically significant survival differences (30, 22 and 6 months, respectively). A total of 43.4% had undergone metastasectomy, mostly incomplete. Risk group affiliation was correlated with response to treatment. Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer undergoing either immunotherapy or targeted treatment.


Cancer Treatment Reviews | 2010

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Manuela Schmidinger; Joaquim Bellmunt

The plethora of novel agents recently approved for the management of metastatic renal cell carcinoma (RCC) has changed the therapeutic landscape in this disease. The plethora of targets some of these agents inhibit can result in a wide range of side effects. While these novel therapies can be viewed as inhibitors of angiogenesis that directly or indirectly target the vascular endothelial growth factor (VEGF) pathway, their individual mechanisms of action (MoA) are key to defining their side-effect profiles. Direct VEGF inhibition with the anti-VEGF monoclonal antibody bevacizumab, is primarily associated with side effects related to the precise inhibition of VEGF, such as proteinuria, hypertension and minor bleeding events. In contrast, non-VEGF-related side effects are observed with agents inhibiting multiple receptor tyrosine kinases (sunitinib, sorafenib, axitinib and pazopanib) and mammalian target of rapamycin inhibitors (temsirolimus and everolimus); these include diarrhoea, skin rash, stomatitis, hand-foot skin reaction, hypothyroidism, and haematological and metabolic abnormalities. This review discusses the MoA of these novel therapies and how a greater understanding of MoA may help to predict the range and type of side effects, develop combinations of agents with acceptable tolerability, enable a more rational approach to patient selection, and allow the development of effective side-effect management strategies.


Journal of Neuro-oncology | 2003

Psychometric- and Quality-of-life Assessment in long-term Glioblastoma survivors

Manuela Schmidinger; Leo Linzmayer; Alexander Becherer; Barbara Fazeny-Doerner; Negar Fakhrai; Daniela Prayer; Monika Killer; Karl Ungersboeck; Karin Dieckmann; Christine Marosi

AbstractBackground: Multimodal treatment of patients with glioblastoma multiforme (GBM) allows an increasing number of patients to survive beyond one year. On account of various neurological and psychophysiological impairments, however, these patients may not benefit in terms of quality of life (QOL). We evaluated the subjective QOL, clinical psychophysiological and cognitive functions in patients with GBM surviving 18 months after diagnosis. Patients and methods: Thirteen patients underwent psychophysiological and psychometric measurements for central-nervous activation, habituation of skin-conductance reaction, crystallized intelligence, verbal and psychovisual memory. QOL was assessed by the symptom check-list for somatization (SCS-Score). Results: We found various impairments such as central-nervous deactivation (n = 9) or high activation (n = 3), psychovegetative overexcitement (n = 3) or attenuation (n = 1), reduced verbal (n = 5) and/or psychovisual (n = 5) memory and loss in attention (n = 7) or concentration (n = 5). Severe physical symptoms (grade 5) were fatigue, convulsion, headache, nausea and micturition difficulties. Eleven patients expressed high satisfaction with life in general, whereas only 4 were satisfied with their general state of health. All patients were independent and 8 patients returned to work. Conclusion: Despite various psychophysiological and cognitive impairments, subjective QOL appears mostly unaffected in this patient setting.


Cancer Investigation | 2010

Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice

Manuela Schmidinger; Dirk Arnold; Cezary Szczylik; John Wagstaff; Alain Ravaud

ABSTRACT Sunitinib is a reference standard of care for the treatment of metastatic renal cell carcinoma (mRCC). While the tolerability of sunitinib is consistent across clinical studies, the impact of tolerability on clinical benefit necessitates effective therapy management, focusing on optimization of dosing, treatment duration, and management of adverse events. Managing individual tolerability concerns in clinical practice should include patient education and practical management strategies. We review the sunitinib tolerability profile in mRCC and describe practical strategies to manage adverse events in order to maximize clinical benefit. These strategies may allow long-term sunitinib treatment, thereby optimizing the available clinical efficacy.


British Journal of Cancer | 2001

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma

Manuela Schmidinger; Catharina Wenzel; Gottfried J. Locker; F. Muehlbacher; R. Steininger; Michael Gnant; R Crevenna; Alexandra C. Budinsky

We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m2 PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted.


Wiener Medizinische Wochenschrift | 2003

Aerobic Exercise as Additive Palliative Treatment for a Patient with Advanced Hepatocellular Cancer

Richard Crevenna; Manuela Schmidinger; M Keilani; Martin Nuhr; Hakan Nur; Carina Zöch; Christoph C. Zielinski; Veronika Fialka-Moser; Michael Quittan

SummaryAerobic exercise is known to improve biopsychosocial outcomes in cancer patients. Currently, exercise is not regarded as a quality-of-life intervention for patients with advanced cancer. The aim of this case study was to determine the feasibility and effects of an aerobic exercise programme for a patient with advanced hepatocellular cancer.After written informed consent, a 55-year-old male patient with advanced hepatocellular carcinoma participated in an aerobic exercise programme of precise intensity, duration and frequency, consisting of ergometer cycling 2 times a week, carried out for a period of 6 weeks. Exercise testing and a 6-min walk were performed, and the patient’s quality of life was assessed.The feasibility, safety and beneficial effects of the programme were proven for this patient. At the end of the exercise programme, peak work capacity had increased by 20.3%. The patient has experienced an improvement in physical performance, which was underlined by the 6-min walk. Quality of life has been improved (physical functioning, vitality, mental health, role functioning/ emotional, social functioning).Knowledge about the benefits of aerobic exercise for patients suffering from advanced cancer is not yet widespread. Nevertheless, aerobic exercise initiated and executed with appropriate care may serve as a useful additional means of palliative treatment in some patients with advanced cancer.ZusammenfassungAerobes Ausdauertraining hat bekannte positive Effekte auf biopsychosoziale Parameter von Krebspatienten. Derzeit gilt Trainingstherapie nicht als lebensqualitätsverbessernde Maßnahme für Patienten mit fortgeschrittenen Karzinomen. Ziel dieser Fallstudie war es, die Machbarkeit und Effekte eines aeroben Ausdauertrainingsprogramms bei einem Patienten mit fortgeschrittenem hepatozellul7#x00E4;ren Karzinom zu bestimmen. Nach schriftlicher Einwilligung nahm ein 55jähriger männlicher Patient mit fortgeschrittenem hepatozellulärem Karzinom an einem aeroben Ausdauertraining, das nach den Regeln der medizini-schen Trainingslehre durchgeführt wurde, teil. Dabei handelte es sich um ein Fahrradergometertraining, welches zweimal wöchentlich über einen Zeitraum von 6 Wochen durchgeführt wurde. Ergometrien, sechsminütige Gehtests sowie Lebensqualitätsuntersuchungen wurden durchgeführt. Machbarkeit, Sicherheit und positive Effekte des Trainingsprogramms konnten für diesen Patienten bewiesen werden. Nach Beendigung des Trainingsprogramms hatte sich die Leistungsfähigkeit des Patienten um 20,3% verbessert. Der Patient gab eine deutliche Verbesserung seiner körperlichen Leistungsfähigkeit an, was durch das Ergebnis des sechsminütigen Gehtests unterstrichen wurde. Die Lebensqualität verbesserte sich in den Domänen „Körperliche Leistungsfähigkeit“, „Vitalität“, „Mentale Gesundheit“, „Emotionale Rollenfunktion“ und „Soziale Kompetenz“. Das Wissen um positive Effekte aeroben Ausdauertrainings bei Patienten mit fortgeschrittenen Karzinomen und infauster Prognose ist derzeit noch nicht stark verbreitet. Dennoch kann aerobes Ausdauertraining, wenn es entsprechend den Gesetzen der medizinischen Trainingslehre durchgeführt wird, eine sinnvolle Ergänzung in der palliativen Behandlung mancher Patienten mit fortgeschrittener Krebserkrankung darstellen.

Collaboration


Dive into the Manuela Schmidinger's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gottfried J. Locker

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Catharina Wenzel

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Richard Crevenna

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christoph Zielinski

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

M Keilani

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge